Table 1.
Patient and treatment characteristics
| Variable | Without 1p/19q Codeletions (n = 51) | With 1p/19q Codeletions (n = 37) | P |
|---|---|---|---|
| Age, y, at the time of radiotherapy | |||
| 20–39 | 30 (58%) | 11 (30%) | .020 |
| 40–49 | 13 (25%) | 13 (35%) | |
| 50+ | 8 (16%) | 13 (35%) | |
| Gender | |||
| Male | 27 (53%) | 25 (68%) | .19 |
| Female | 24 (47%) | 12 (32%) | |
| WHO grade | |||
| II | 18 (35%) | 10 (27%) | .49 |
| III | 33 (65%) | 27 (73%) | |
| Tumor volume at diagnosis | |||
| Range (cm3)a | 5–212 | 5–163 | .46 |
| Median (cm3)a | 48 | 28 | |
| Resection | |||
| Gross total resection | 26 (51%) | 20 (54%) | .77 |
| Partial resection | 19 (37%) | 12 (32%) | |
| Biopsy | 6 (12%) | 4 (11%) | |
| AutoLITTb | 0 | 1 (3%) | |
| T2 abnormality at time of adjuvant therapy | |||
| Range (cm3)c | 0–146 | 0–40 | .48 |
| Median (cm3)c | 16 | 9 | |
| Location | |||
| Frontal lobe | 35 (69%) | 33 (89%) | .038 |
| Not frontal lobe | 16 (31%) | 4 (11%) | |
| p53 | |||
| p53 overexpression | 28/34 (82%) | 4/16 (25%) | .00027 |
| Normal p53 expression | 6/34 (18%) | 12/16 (75%) | |
| Radiation | |||
| Range (cGy)d | 5400–6134 | 5000–6300 | .48 |
| Median (cGy)d | 5940 | 5940 | |
| Chemotherapy | |||
| Concurrent chemotherapy | 42 (82%): 40 with temozolomide, 2 with hydroxyurea | 32 (86%): 31 with temozolomide, 1 with hydroxyurea | .29 |
| Radiation followed by chemotherapy | 6e (12%): 5 with temozolomide, 1 with PCV | 1 (3%): 1 with temozolomide | |
| Radiation alone | 3 (6%) | 4 (11%) | |
aData on tumor volume prior to resection were available for 41/51 tumors without 1p/19q codeletions and 33/37 tumors with 1p/19q codeletions.
bAutoLITT is a trademark of Monteris Medical, Plymouth, MN, and is an FDA-approved system that is used to thermally ablate brain tumors via a fiber-optic laser probe.
cData on T2 abnormality at the time of adjuvant therapy were available for 42/51 tumors without 1p/19q codeletions and 30/37 tumors with 1p/19q codeletions.
dData on dose administered were available for 39/51 tumors without 1p/19q codeletions and 33/37 tumors with 1p/19q codeletions.
eIn 1 of these 6 cases, it is unclear whether temozolomide was started before or after completion of radiotherapy. cGy, centigray; PCV, procarbazine, lomustine, and vincristine.